Search
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnserum uric acid levels with a xanthine oxidase inhibitor alone. … Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target
Amylocaine
go.drugbank.com/drugs/DB09088ApprovedWithdrawnElsewhere in English speaking countries it was referred to as Stovaine, given the meaning of the French word 'fourneau' as 'stove' in English [L1882]. … Finally, in 1903 the world's first synthetic and non-addictive local anesthetic, amylocaine, was synthesized and patented under the name Forneaucaine by Ernest Fourneau at the Pasteur Institute [L1882]
Streptomycin
go.drugbank.com/drugs/DB01082ApprovedInvestigationalVet approvedStreptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s. … [A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedDTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label]. … Detecting sentinel lymph node (SLN) is clinically useful in the prognosis and management of the disease, as it is considered as the first lymph node that receives afferent lymphatic drainage from a primary
Irinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigational[A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer. … Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of [camptothecin], which is extracted from the Chinese tree _Camptotheca acuminate_.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A9 Substrates with a Narrow Therapeutic IndexProducts: DARITEX-A, IRINOTECAN MYLAN GENERICSInsulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigationalInsulin icodec is an ultra long-acting basal insulin analogue. … [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102]
Iroxanadine
go.drugbank.com/drugs/DB05444ExperimentalBRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC).
Etoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalA semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index